β-Cell Function Derived From Routine Clinical Measures Reports and Predicts Treatment Response to Immunotherapy in...

Area of Science:

• Endocrinology
• Immunology
• Clinical Trial Design

Background:

• Baricitinib demonstrates potential in preserving pancreatic beta-cell function in new-onset type 1 diabetes.
• Assessing beta-cell preservation and predicting treatment response are crucial for optimizing immunotherapy.

Purpose of the Study:

• To identify simple, routine clinical measures for assessing beta-cell preservation.
• To determine predictors of treatment response to baricitinib and other immunotherapies in type 1 diabetes.

Main Methods:

• Utilized data from the BAricitinib in Newly DIagnosed Type 1 diabetes (BANDIT) trial.
• Employed linear regression and receiver operator characteristic analysis to identify and validate therapeutic predictors.
• Validated findings using data from rituximab, abatacept, and antithymocyte globulin trials.

Main Results:

• Quantitative response score (QRS), fasting C-peptide, and model-estimated C-peptide (CPest) effectively differentiated treatment groups.
• The Beta2 score, incorporating glucose, C-peptide, HbA1c, and insulin dose, accurately predicted treatment efficacy (AUC 0.864).
• A 6.2% decrease in Beta2 score at week 12 predicted significant improvements in HbA1c and insulin use in immunotherapy trials.

Conclusions:

• Fasting C-peptide and CPest are efficient outcome measures for immunotherapy trials.
• The Beta2 score can predict treatment response, enabling adaptive trial designs and clinical decision-making for type 1 diabetes management.